Skip to content

AI Drug Discovery

Know which series is worth the synthesis budget - before you spend it

USD 30–85K per system · 4–8 weeks · Free-energy ranking and design recommendations

At a glance

Price band
USD 30–85K per system
Duration
4–8 weeks
Deliverable
Free-energy ranking
Data package
Full trajectories

Indicative list price. Final scope and price confirmed in the proposal.

Talk to a scientist

The problem

Why teams buy this

Docking scores are poor predictors of real affinity. Medicinal chemistry programmes routinely commit months of synthesis to a series that was never going to hold in the binding pocket - and the data that would have shown it was affordable all along.

What you get

Deliverables, not activity

  • A simulation report with trajectory and interaction-stability analysis
  • Relative binding free-energy ranking across your series
  • Interaction and stability maps
  • Structure-based design recommendations for the next chemistry cycle
  • The trajectory data package, for your own reanalysis

Who this is for

Structure-based design teams · medicinal chemistry programmes at series-selection · biotech deciding where to spend synthesis budget · academic laboratories needing mechanism evidence for publication or patent.

Proof

Representative result

Four chemical series ranked by free-energy calculation, redirecting a medicinal chemistry programme away from a series that later proved unstable in the pocket.

Representative programme - illustrates typical scope and outcomes; not an individual client account. Client-specific references are available on request under confidentiality.

Enterprise AI for Life Sciences

Ready to Advance Your Drug Discovery Pipeline?

Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.

From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.